Cellectis (CLLS) Profit After Tax (2015 - 2026)
Cellectis (CLLS) posted quarterly Profit After Tax of -$17.8 million for Q1 2026, up 2.0% year-over-year from -$17.4 million in Q1 2025, and up 32.5% quarter-over-quarter from -$26.3 million in Q4 2025.
Cellectis (CLLS) Profit After Tax (2015 - 2026) Analysis & Trends
Cellectis' Profit After Tax history runs 12 years deep, the most recent figure standing at -$17.8 million for Q1 2026.
- In Q1 2026, Profit After Tax rose 2.0% year-over-year to -$17.8 million; the TTM figure through Mar 2026 stood at -$67.2 million (down 11.07% YoY), while the FY2025 annual figure was -$67.6 million, down 83.87% from the prior year.
- Profit After Tax for Q1 2026 stood at -$17.8 million, up from -$26.3 million in the prior quarter.
- The five-year high for Profit After Tax was $5.9 million in Q4 2024, with the low at -$50.2 million in Q4 2023.
- The 5-year median for Profit After Tax is -$23.1 million (2024), against an average of -$20.8 million.
- The sharpest annual moves came in 2024 and 2025: Profit After Tax soared 117.35% in 2024, then slumped 544.41% in 2025.
- Cellectis' Profit After Tax stood at -$28.6 million in 2022, then slumped by 75.73% to -$50.2 million in 2023, then jumped by 111.8% to $5.9 million in 2024, then plunged by 544.41% to -$26.3 million in 2025, then soared by 32.5% to -$17.8 million in 2026.
- Business Quant data shows CLLS's Profit After Tax at -$17.8 million in Q1 2026, -$26.3 million in Q4 2025, and $589000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 472.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,087.27 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -16.62 Mn |
| 10 | Cellectis | 306.61 Mn | 120.95 Mn | - | -17.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -17.77 Mn |
| Dec 31, 2025 | -26.32 Mn |
| Sep 30, 2025 | 589,000.00 |
| Jun 30, 2025 | -23.74 Mn |
| Mar 31, 2025 | -18.13 Mn |
| Dec 31, 2024 | 5.92 Mn |
| Sep 30, 2024 | -23.06 Mn |
| Jun 30, 2024 | -25.27 Mn |
| Mar 31, 2024 | 5.64 Mn |
| Dec 31, 2023 | -50.19 Mn |
| Sep 30, 2023 | -17.48 Mn |
| Jun 30, 2023 | -16.64 Mn |
| Mar 31, 2023 | -32.53 Mn |
| Dec 31, 2022 | -28.56 Mn |
| Sep 30, 2022 | -31.27 Mn |
| Jun 30, 2022 | -19.45 Mn |
| Mar 31, 2022 | -34.76 Mn |
| Dec 31, 2021 | -28.08 Mn |
| Sep 30, 2021 | -40.07 Mn |
| Jun 30, 2021 | -41.61 Mn |